D At California Biotech Firm

California Biotech Firm Author: KAREN YOUNG KREEGER Igor Gonda, 47, assumed the newly created position of vice president of research and development at Aradigm Corp., a privately held biotech firm in Hayward, Calif., on September 25. Gonda is leaving his post as senior scientist and group leader of pharmaceutics at South San Francisco, Calif., biotech giant Genentech Inc. in order to develop new drug-delivery systems at the company. Aradigm currently employs about 25 scientists. Gonda will be

Written byKaren Young Kreeger
| 2 min read

Register for free to listen to this article
Listen with Speechify
0:00
2:00
Share

California Biotech Firm Author: KAREN YOUNG KREEGER

Igor Gonda, 47, assumed the newly created position of vice president of research and development at Aradigm Corp., a privately held biotech firm in Hayward, Calif., on September 25. Gonda is leaving his post as senior scientist and group leader of pharmaceutics at South San Francisco, Calif., biotech giant Genentech Inc. in order to develop new drug-delivery systems at the company.

Aradigm currently employs about 25 scientists. Gonda will be in charge of about half of them. "To have the opportunity to lead the research group in such a unique company is very attractive to me," he says. He adds that he is making the move so he can pursue what intrigues him the most scientifically-the design of aerosol-delivery systems for the treatment of respiratory diseases.

"The most exciting aspect for me in my new job will be to bring together what the ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Meet the Author

Published In

Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies